Table 1.

Baseline Clinical Characteristics of the Study Population

	Dapagliflozin Group (n = 42)	Control Group (n = 38)	P
Age, years	60.5 ± 11.0	61.4 ± 9.8	.680
Gender, male/female, n (%)	19/23 (45.2/54.8)	15/23 (39.5/60.5)	.602
Current smoking, n (%)	10 (23.8)	8 (21.1)	.768
Hypertension, n (%)	20 (47.6)	17 (44.7)	.796
Body weight, kg	83.3 ± 13.8	81.7 ± 12.1	.379
Body mass index, kg/m2	29.6 ± 4.7	29.4 ± 5.0	.587
Duration of diabetes, years	8.4 ± 3.1	8.6 ± 3.5	.757
Fasting plasma glucose, mg/dL	154.5 ± 46.9	156.1 ± 42.0	.877
HbA1c, %	7.81 ± 1.37	7.94 ± 1.31	.672
Total cholesterol, mg/dL	192.1 ± 38.1	190.5 ± 39.5	.852
High-density lipoprotein cholesterol, mg/dL	44.5 ± 12.0	45.5 ± 12.2	.727
Low-density lipoprotein cholesterol, mg/dL	121.2 ± 29.9	116.1 ± 32.8	.476
Triglycerides, mg/dL	131.9 ± 63.9	134.1 ± 68.6	.880
Systolic BP, mm Hg	128.5 ± 19.9	129.3 ± 22.0	.850
Diastolic BP, mm Hg	77.9 ± 11.8	79.3 ± 14.6	.617
Resting HR, beats/min	75.2 ± 11.4	73.7 ± 10.6	.541
Left ventricular ejection fraction, %	63.3 ± 5.7	62.4 ± 5.2	.522
Interventricular septum thickness, mm	11.2 ± 1.9	10.9 ± 1.8	.470
Left ventricular posterior wall thickness, mm	10.4 ± 1.6	10.2 ± 1.6	.698
Abnormal cardiovascular autonomic reflex tests
HR response to breathing, n (%)	28 (66.7)	22 (57.9)	.418
HR response to standing, n (%)	15 (35.7)	18 (47.4)	.290
HR response to Valsalva maneuver, n (%)	19 (45.2)	16 (42.1)	.778
BP response to standing, n (%)	9 (21.4)	12 (31.6)	.303
BP response to isometric exercise, n (%)	5 (11.9)	2 (5.3)	.436
Current medical therapy
ACEI or ARB, n (%)	17 (40.5)	16 (42.1)	.882
Dihydropyridine CCB	18 (42.9)	18 (47.4)	.685
Diuretics, n (%)	15 (35.7)	12 (31.6)	.696
Metformin, n (%)	37 (88.1)	34 (89.5)	.846
DPP-4 inhibitors/sulfonylureas/thiazolidinediones, n (%)	19 (45.2)	20 (52.6)	.509
Statins, n (%)	23 (54.8)	27 (71.1)	.133

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BP, blood pressure; CCB, calcium channel blockers; DPP-4, dipeptidyl peptidase-4; HR, heart rate; n, numbers.